[go: up one dir, main page]

DE60035485D1 - IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407 - Google Patents

IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407

Info

Publication number
DE60035485D1
DE60035485D1 DE60035485T DE60035485T DE60035485D1 DE 60035485 D1 DE60035485 D1 DE 60035485D1 DE 60035485 T DE60035485 T DE 60035485T DE 60035485 T DE60035485 T DE 60035485T DE 60035485 D1 DE60035485 D1 DE 60035485D1
Authority
DE
Germany
Prior art keywords
mycobacterium
relates
differentially expressed
present
antigenes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60035485T
Other languages
English (en)
Other versions
DE60035485T2 (de
Inventor
Peter Jungblut
Stefan H Kaufmann
Ulrich Schaible
Hans Mollenkopf
Baerbel Raupach
Ursula Zimny-Arndt
Stephanie Lamer
Jens Mattow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Publication of DE60035485D1 publication Critical patent/DE60035485D1/de
Application granted granted Critical
Publication of DE60035485T2 publication Critical patent/DE60035485T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
DE60035485T 1999-01-29 2000-01-28 IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407 Expired - Lifetime DE60035485T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99101590 1999-01-29
EP99101590 1999-01-29
PCT/EP2000/000690 WO2000044392A2 (en) 1999-01-29 2000-01-28 Identification of specific differentially expressed mycobacterial antigens

Publications (2)

Publication Number Publication Date
DE60035485D1 true DE60035485D1 (de) 2007-08-23
DE60035485T2 DE60035485T2 (de) 2008-03-20

Family

ID=8237440

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60035485T Expired - Lifetime DE60035485T2 (de) 1999-01-29 2000-01-28 IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407

Country Status (10)

Country Link
US (1) US7772386B1 (de)
EP (1) EP1146889B1 (de)
JP (1) JP2002534994A (de)
AT (1) ATE366583T1 (de)
AU (1) AU2667600A (de)
CA (1) CA2361246C (de)
DE (1) DE60035485T2 (de)
DK (1) DK1146889T3 (de)
ES (1) ES2288842T3 (de)
WO (1) WO2000044392A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2135947A1 (de) * 2008-06-17 2009-12-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Antagonisten bakterieller Sequenzen
ITRM20100411A1 (it) * 2010-07-23 2012-01-24 Massimo Amicosante Uso di sequenze amminoacidiche da mycobacterium tuberculosis o dei loro corrispondenti acidi nucleici per la diagnosi e la prevenzione di infezione tubercolare, relativo kit diagnostico e vaccino.
CA2941236A1 (en) * 2014-03-07 2015-09-11 Institute For Systems Biology Point of care assays to detect the status of tuberculosis infection
US11679150B2 (en) 2020-03-03 2023-06-20 The United States Of America, As Represented By The Secretary Of Agriculture Mycoplasma bovis vaccine product
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
KR102405798B1 (ko) * 2020-06-22 2022-06-08 주식회사 미코라파 Rv2882c-Rv2005c 융합 단백질을 포함하는 결핵 면역 치료용 조성물
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
KR102878370B1 (ko) * 2022-06-17 2025-10-31 주식회사 미코라파 면역활성 부위 융합 단백질을 포함하는 결핵 백신 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2624759B2 (ja) * 1988-03-30 1997-06-25 味の素株式会社 Ｂｃｇ菌由来のｍｐｂ６４蛋白及びその製造法
FR2752425B1 (fr) 1996-08-19 1998-11-13 Pasteur Institut Fragments d'acides nucleiques specifiques de mycobacteries membres du complexe m. tuberculosis et leurs applications pour la detection et le diagnostic differentiel des membres du complexe m. tuberculosis

Also Published As

Publication number Publication date
AU2667600A (en) 2000-08-18
CA2361246A1 (en) 2000-08-03
ES2288842T3 (es) 2008-02-01
WO2000044392A2 (en) 2000-08-03
DE60035485T2 (de) 2008-03-20
EP1146889A2 (de) 2001-10-24
WO2000044392A3 (en) 2000-12-07
DK1146889T3 (da) 2007-10-22
EP1146889B1 (de) 2007-07-11
JP2002534994A (ja) 2002-10-22
CA2361246C (en) 2013-04-16
US7772386B1 (en) 2010-08-10
ATE366583T1 (de) 2007-08-15

Similar Documents

Publication Publication Date Title
Brandt et al. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population
Hanff et al. Humoral immune response in human syphilis to polypeptides of Treponema pallidum
JP4283872B2 (ja) 微生物蛋白質と、この蛋白質を産生する微生物と、該蛋白質のワクチンおよび結核検出での利用
BRPI0208301A8 (pt) vacinas de ácido nucléico para prevenção de infecção por flavivírus
DK0950068T3 (da) Kollagen-bindende proteinsammensatninger og fremgangsmade til anvendelse
DE69630457D1 (de) Verbindungen zur immunotherapie und diagnose von tuberkulose
FI895050A0 (fi) Diagnostiska preparat och vaccin foer mykobakterier i folkhaelso-, medicinsk och veterinaermedicinsk praxis.
Huang et al. Immunization with cell‐free‐generated vaccine protects from Porphyromonas gingivalis‐induced alveolar bone loss
ATE526994T1 (de) Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
DE60120621D1 (de) Lawsonia intracellularis Impfstoff
WO2002072036A3 (en) Compositions and methods comprising west nile virus polypeptides
DE60035485D1 (de) IDENTIFIZIERUNG VON SPEZIFISCHEN DIFFERENZIELL EXPRIMIERTEN ANTIGENEN AUS MYCOBACTERIUM UND MEDIZINISCHE VERWENDUNG DER MYCOBAKTERIUMPROTEINE Rv0068 UND Rv3407
Cho et al. Extracellular vesicle-associated antigens as a new vaccine platform against scrub typhus
CN101451145A (zh) 基于t细胞表位的结核基因疫苗及其制备方法和应用
US7862828B2 (en) Allergy vaccines containing hybrid polypeptides
KR100366482B1 (ko) 백신으로서 정제된 분류가능하지 않은 헤모필루스 인프루엔자 p5단백질, 및 그의 정제방법
WO2004020609A3 (en) Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
ATE450545T1 (de) Impfstoff mit lawsonia intracellularis- untereinheit
EP2391640B1 (de) Clostridium-chauvoei-polypeptid, dna, die das polypeptid kodiert, und vakzin, das das polypeptid umfasst
Tafuku et al. Japanese encephalitis virus structural and nonstructural proteins expressed in Escherichia coli induce protective immunity in mice
KR20240009981A (ko) 아미노산, 뉴클레오티드 및 이를 발현하는 벡터, 및 사르베코바이러스 감염을 예방하는 데에 있어서의 이의 용도
WO2003102025A1 (en) Protein inducing cell death of helicobacter pylori
Nassrullah et al. Cloning, Sequencing and Expression of the Brucella Melitensis Novel Lomr Protein.
BR0110791A (pt) Composição, métodos para induzir uma resposta imune em um indivìduo contra um imunogene, para modular o sistema imune de um indivìduo e para imunizar um indivìduo contra um patógeno, vacina recombinante, e patógeno atenuado vivo
Asma et al. Analysis of outer membrane proteins of Pasteurella multocida strains isolated from buffaloes affected with hemorrhagic septicemia

Legal Events

Date Code Title Description
8364 No opposition during term of opposition